Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agents

Han, Young A; Singh, Mukul; Saxena, Brij B.

doi:10.1016/j.contraception.2007.04.006

Cited by 48 publications

(29 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of IVRs for controlled release of microbicides is well advanced, as demonstrated by the evaluation of a 28-day DPV releasing IVR in an upcoming phase III efficacy trial evaluating the ability of this product to prevent transmission of HIV. Newer IVR designs are addressing the need to release more than one drug; this approach should lead to more effective microbicide products as well as multipurpose protection technologies capable of addressing two different indications (e.g., prevention of HIV transmission and contraception) [7,49]. Fig.…”

Section: Discussionmentioning

confidence: 98%

Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections

Friend

2011

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Intravaginal rings (IVRs) are a dosage form used to locally or systemically deliver drugs in the vagina. They are capable of releasing one or more drugs over an extended period of time (from several weeks to a year or longer). Contraceptive IVRs are currently gaining popularity due to the success of the contraceptive product NuvaRing®. Delivery of contraceptives from IVRs should promote compliance/adherence, and they also provide effective cycle control and symptom relief (menorrhagia, dysmenorrheal, and polycystic ovarian syndrome). Vaginal delivery of proteins from IVRs was first explored in an attempt to deliver IgG2a antibody intravaginally to neutralize herpes simplex virus 2. More recently, IVRs capable of releasing antibodies and recombinant proteins potentially along with low molecular weight microbicides are under investigation for prevention of HIV-1 transmission. Vaginal delivery of microbicides has been studied with several drugs most notably the non-nucleoside reverse transcriptase inhibitor dapivirine. Another drug capable of blocking transmission of HIV-1 when released from IVRs is tenofovir. Finally, combinations of drugs with different indications (i.e., multipurpose prevention technologies) are actively being pursued.

show abstract

Section: Discussionmentioning

confidence: 98%

Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections

Friend

2011

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

show abstract

“…A third design is a pod insert design whereby tablets or pods containing API are inserted into VRs to improve loading and control release of drug from the VR (Moss et al 2012). Lastly, there are novel approaches to ring designs such as multi-segmented rings and hydrogel vaginal rings (Han et al 2007;Saxena et al 2009). The most effective choice of polymer for a given microbicide depends on the solubility of the drug in the polymer, and on whether the drug has a low enough molecular weight to diffuse through the polymer (Fetherston et al 2010).…”

Section: Vaginal Ringsmentioning

confidence: 98%

“…There are other dosage forms such as ARV-loaded SILCS diaphragm (Schwartz et al 2008a), hydrogel vaginal rings (Han et al 2007;Saxena et al 2009), and electrospun fiber meshes containing drugs that are currently under development within the microbicide field. The following section describes a small portion of these unique drug/device combinations to demonstrate some of the creative approaches taken to supply the HIV prevention field with options for novel dosage forms and multi-prevention technologies.…”

Section: Thermoplastic Ringsmentioning

confidence: 99%

Microbicide Dosage Forms

Rohan

Devlin

Yang

2013

Current Topics in Microbiology and Immunology

View full text Add to dashboard Cite

Microbicides are topically applied, user controlled dosage forms that are being developed to prevent the transmission of HIV during coitus. Early candidates focused on coitally dependent dosage forms such as gels and creams. More recent development has focused on broadening the coitally dependent options through the introduction of films and fast dissolving tablets. Additionally, it has become important to have longer acting products to minimize the burden of user compliance and thus vaginal rings have been developed providing sustained delivery of antiretroviral drugs. This chapter discusses the history of microbicides along with a detailed description of coitally dependent products, gels, films, tablets diaphragms, as well as coitally independent dosage forms such as vaginal rings and the introduction of a new technology, electrospun fibers.

show abstract

“…Each sample was measured in triplicate. Dilution was done in ratio of 10: 3.7 ml with pH 4.5 citrate buffer and [30,31].…”

Section: Optimization Data Analysis and Validation Of Optimization Modelmentioning

confidence: 99%

Optimization of curcumin loaded vaginal in-situ hydrogel by box-behnken statistical design for contraception

Patel

Thakkar

Moradiya

et al. 2015

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agents

Cited by 48 publications

References 20 publications

Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections

Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections

Microbicide Dosage Forms

Optimization of curcumin loaded vaginal in-situ hydrogel by box-behnken statistical design for contraception

Contact Info

Product

Resources

About